These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22590487)

  • 1. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer.
    Abramson VG; Mayer IA
    Ther Adv Med Oncol; 2012 May; 4(3):139-47. PubMed ID: 22590487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer.
    Labidi S; Mejri N; Lagha A; Daoud N; El Benna H; Afrit M; Boussen H
    Breast Care (Basel); 2016 Dec; 11(6):418-422. PubMed ID: 28228709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
    Larionov AA
    Front Oncol; 2018; 8():89. PubMed ID: 29670855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
    Wu J; Kong R; Tian S; Li H; Wu K; Kong L
    Chin J Cancer Res; 2019 Dec; 31(6):878-891. PubMed ID: 31949390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
    J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal treatment of early stage HER2-positive breast cancer.
    Pernas S; Barroso-Sousa R; Tolaney SM
    Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
    Mates M; Fletcher GG; Freedman OC; Eisen A; Gandhi S; Trudeau ME; Dent SF
    Curr Oncol; 2015 Mar; 22(Suppl 1):S114-22. PubMed ID: 25848335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 aberrations in cancer: implications for therapy.
    Yan M; Parker BA; Schwab R; Kurzrock R
    Cancer Treat Rev; 2014 Jul; 40(6):770-80. PubMed ID: 24656976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.
    Sapna F; Athwal PSS; Kumar M; Randhawa S; Kahlon S
    Cureus; 2020 Aug; 12(8):e9522. PubMed ID: 32905036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
    Kim M; Agarwal S; Tripathy D
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):27-33. PubMed ID: 24335887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in novel targeted therapies for HER2-positive breast cancer.
    Murphy CG; Morris PG
    Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
    Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.
    Nahta R
    ISRN Oncol; 2012; 2012():428062. PubMed ID: 23227361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
    Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC
    J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.